Improved solvent systems for commercially viable perovskite photovoltaic modules
Collaborative Innovation Center of Advanced Microstructures · Nanjing University · +8 more institutions
Abstract
Commercializing perovskite photovoltaics requires overcoming three critical barriers: the use of toxic solvents in manufacturing, variations in perovskite film quality across large areas, and limited operational reliability. Here, we address these challenges by developing a green solvent-based (γ-valerolactone/2-methyl tetrahydrofuran/dimethylsulfoxide) ink and a solvent-confinement edge-protection strategy, demonstrating large-scale manufacturing of defect-minimized perovskite films under ambient-air conditions. These approaches enabled the production of 7200-square-centimeter perovskite photovoltaic modules that achieved a total-area steady-state efficiency of 17.2% (certified by the National Renewable…
Citation impact
- FWCI
- 38.81
- Percentile
- 100%
- References
- 61
Authors
27- YWYinke WangCorresponding
Collaborative Innovation Center of Advanced Microstructures, Nanjing University
- YLYe Liu
Suzhou University of Technology, Collaborative Innovation Center of Advanced Microstructures, Nanjing University
- YLYe LiuCorresponding
Suzhou University of Technology, Collaborative Innovation Center of Advanced Microstructures, Nanjing University
- XLXin LuoCorresponding
Suzhou University of Technology, Collaborative Innovation Center of Advanced Microstructures, Nanjing University
- KXKe XiaoCorresponding
University of Victoria, Collaborative Innovation Center of Advanced Microstructures, Nanjing University
Topics & keywords
- Perovskite (structure)
- Photovoltaic system
- Photovoltaics
- Renewable energy
- Reliability (semiconductor)
- Environmentally friendly
- Quality (philosophy)
Funding
- NNNational Natural Science Foundation of ChinaAward: U21A2076
- CPChina Postdoctoral Science FoundationAwards: 2023M731579, BX20230157
- NSNatural Science Foundation of Jiangsu ProvinceAwards: BE2022021, BE2022026, BK20232022
- FCFrontiers Clinical and Translational Science Institute, University of KansasAwards: 2024ZD06, DLTD2109
- NKNational Key Research and Development Program of ChinaAward: 2022YFB4200304
- FRFundamental Research Funds for the Central UniversitiesAwards: 0213/14380206, 0205/14380252
- NSNational Science Fund for Distinguished Young ScholarsAward: T2325016